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Abstract
Background and Methodology: The 719Arg allele of KIF6 (rs20455) was associated with coronary events in Caucasian
participants of five prospective studies. We investigated whether this KIF6 variant was associated with non-fatal myocardial
infarction (MI) in a case-control study of an admixed population from the Central Valley of Costa Rica. Genotypes of the KIF6
variant were determined for 4,134 men and women. Cases (1,987) had survived a first MI; controls (2,147) had no history of
MI and were matched to cases by age, sex, and area of residence. We tested the association between the KIF6 719Arg allele
and non-fatal MI by conditional logistic regression and adjusted for admixture of founder populations.
Principal Findings: Compared with the reference Trp/Trp homozygotes, KIF6 719Arg carriers were not at significantly higher
risk for non-fatal MI in this study after adjustment for traditional risk factors or admixture (OR=1.12; 95%CI, 0.98–1.28).
Heterozygotes of the KIF6 Trp719Arg variant were at increased risk of non-fatal MI: the adjusted odds ratio was 1.16 (95%
confidence interval, 1.01–1.34), but this association would not be significant after a multiple testing correction.
Conclusions/Significance: We found that carriers of the KIF6 719Arg allele were not at increased risk of non-fatal MI in a
case-control study of Costa Ricans living in the Central Valley of Costa Rica.
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Introduction
Kinesins are a superfamily of homodimeric motor proteins that
transport cellular cargos (e.g., proteins, vesicles, or organelles)
along microtubules in an ATP dependent process[1]. A single
nucleotide polymorphism (SNP) in the gene for the KIF6
protein—a member of the kinesin 9 family—has been reported
to be associated with coronary heart disease (CHD) and event
reduction during statin therapy[2]. In Caucasians, carriers of the
719Arg allele of this SNP (rs20455) were at increased risk for
coronary events in 5 prospective studies: the Atherosclerosis Risk
in Communities (ARIC) study[3], the Cardiovascular Health
Study (CHS) [4], the Women’s Health Study (WHS)[5], and in the
placebo groups of both the Cholesterol and Recurrent Events
(CARE) study and the West of Scotland Coronary Prevention
Study (WOSCOPS)[2], In contrast to these prospective studies,
KIF6 Trp719Arg was not associated with coronary artery disease
(CAD) in two recently reported case-control studies: the Ottawa
Heart Genomics study[6] and the Welcome Trust Case-Control
Consortium study[7].
Only limited data are available regarding whether the KIF6
719Arg allele is associated with CHD in other ethnic populations.
For example, among African Americans in ARIC, each allele of
KIF6 719Arg increased the risk for incident CHD by 1.23-fold
(95%CI, 0.99–1.52)[3], and among African Americans in CHS,
carriers of the KIF6 719Arg allele had a hazard ratio for incident
myocardial infarction (MI) of 4.14 (90%CI, 0.79–21.77), com-
pared with noncarriers[4]. Thus, although the associations
between the KIF6 719Arg allele and CHD were not statistically
significant in the small African American study populations in
ARIC and CHS, these results suggested that the KIF6 719Arg
allele may be associated with CHD in ethnic populations other
than Caucasians. Therefore, we asked whether the KIF6 719Arg
allele is associated with MI in a Hispanic population from Costa
Rica.
Results
The characteristics of cases with myocardial infarction and
population-based controls from the Central Valley of Costa Rica
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(i.e., matched characteristics) did not differ significantly between
cases and controls (Table 1). Other CHD risk factors (smoking,
history of hypertension, family history of MI, and waist-to-hip
ratio) were higher in cases than in controls (Table 1). The
genotypes of the KIF6 SNP (rs20455) that cause a Trp719Arg
variation did not deviate from the distribution expected under
Hardy–Weinberg equilibrium (P=0.38); the frequency of the
minor allele (KIF6 719Arg) was 0.36 in the control subjects.
We found that carriers of one or two copies of the KIF6 719Arg
variant were not at increased risk of MI (OR=1.12; 95%CI, 0.98–
1.28; Table 2). Although the risk estimate for heterozygotes of the
KIF6 variant (Trp/Arg), compared with major allele homozygotes
(Trp/Trp), was 1.15 (95%CI 1.00–1.33; Table 2) after adjusting
for potentially confounding risk factors and admixture in this
Costa Rican population, this association would not be significant if
corrected for the testing of multiple KIF6 719Arg carrier groups.
Homozygotes of the KIF6 variant (Arg/Arg) were not at increased
risk of MI, compared with major allele homozygotes (Trp/Trp).
Discussion
In contrast to the results reported from 5 prospective studies, we
found that KIF6 719Arg carriers were not at significantly higher
risk for non-fatal MI in this case-control study of a Hispanic
population from Costa Rica after adjustment for traditional risk
factors or admixture. Heterozygotes of the KIF6 Trp719Arg
variant, compared with Trp/Trp homozygotes, were at increased
risk of nonfatal MI (OR=1.16), but this association would not be
significant after a multiple testing correction. Arg/Arg homozy-
gotes of the KIF6 variant were not at increased risk of MI,
compared with Trp/Trp homozygotes.
Although the KIF6 variant has been found to be associated with
CHD in five prospective studies of CHD[2,3,4,5], it was not
associated with CAD in two case-control studies: the Ottawa
Heart Genomics study[6] and the Wellcome Trust Case-Control
Consortium[7]. The Ottawa Heart Genomics case-control study
investigated the association between KIF6 719Arg and MI in a
population with angiographically defined coronary artery disease.
The Wellcome Trust Case-Control Consortium analyzed the
association between KIF6 Trp719Arg and CAD. That KIF6
719Arg was associated with CHD in prospective, but not in case-
control studies, could be explained by either ascertainment biases
or by statin use in the populations from which the cases were
drawn. Statin use would be expected to reduce the likelihood of
observing an association between KIF6 719Arg and CHD because
in 3 randomized studies[2,5], statin therapy significantly reduced
coronary events in KIF6 719Arg carriers but not in noncarriers.
The potential inclusion of individuals on statin therapy is also a
limitation of our Costa Rica study, which may have weakened the
association of the KIF6 variant with MI.
In previous published prospective studies, risk estimates have
been nominally higher for heterozygotes (Trp/Arg) than for
homozygotes (Arg/Arg) in most studies of Trp719Arg (WHS,
CARE, CHS, and WOSCOPS)[2,4,5]. In this study of Costa
Ricans, the risk estimates for heterozygotes and homozygotes of
KIF6 719Arg are consistent with the pattern of these previous
studies. The only prospective study where the observed risk
estimates have been higher for Arg/Arg homozygotes than
heterozygotes of KIF6 Trp719Arg was the ARIC study[3]. The
higher risk estimates for heterozygotes (Trp/Arg) in most studies
could be due to chance. Alternatively, the higher risk estimates for
heterozygotes could indicate that there is a functional difference
between heterodimers and homodimers of the KIF6 protein,
possibly because the Arg-Trp heterodimers differ from Arg-Arg
and Trp-Trp homodimers in their stability or in their ability to
transport cargo. However, the function of the KIF6 protein and its
role in CHD remains to be elucidated.
Admixture in the Costa Rican population did not affect the
association between KIF6 719Arg and MI. Based on historical
records[8,9] and ancestry informative markers[10,11,12], the
population of the Central Valley of Costa Rica is an admixture
of 3 ancestral populations: Southern Europeans, Amerindians and
West Africans. The KIF6 (719Arg) allele frequency of the KIF6
Trp719Arg variant reported in the HapMap database differs
between these populations. The allele frequencies are 38 percent
for Caucasians of Western European decent and 95 percent for
West Africans (Yoruba residing in Ibadan, Nigeria); the allele
frequency for Amerindians from the central valley of Costa Rica
was not available from HapMap. Since the KIF6 719Arg allele
frequency varies according to ancestry, a spurious association
could occur if the admixture of the 3 ancestral populations were
different between cases and controls. However, adjustment for the
degree of admixture did not appreciably change the KIF6 719Arg
risk estimate for MI.
Limitations
Since participants with cardiovascular diseases other than a
history of MI were not excluded from the control group, the risk
estimates obtained in this study may be lower than would have
been observed had a disease-free control group been used. The use
of statins was previously reported to ameliorate the risk of
coronary events in carriers of KIF6 719Arg in CARE and
WOSCOPS[2]. Therefore, statin use in the population might
cause the risk estimates for MI in this study to be underestimated;
however, information on statin use among this population was not
available.
Conclusions
Carriers of the KIF6 719Arg allele were not at increased risk of
non-fatal MI, compared with Trp/Trp homozygotes, in a case-
control study from the Central Valley of Costa Rica. We found no
evidence that admixture within the Costa Rican population
affected these results. Additional studies are need to address why
the association between carriers of the KIF6 719Arg and MI differ
between this and other case-control studies and the previously
reported prospective studies.
Table 1. Characteristics of Cases and Controls.
Controls Cases P Value
1
Characteristic (n=2147) (n=1987)
Age, yrs 58.3611.3 58.3611.0 N/A
2
Male, n (%) 1577 (73) 1474 (74) N/A
2
Current Smoker, n (%) 461 (22) 797 (40) ,0.001
Residence (% rural) 546 (25) 517 (26) N/A
2
History of diabetes, n (%) 309 (14) 488 (25) ,0.001
History of hypertension, n (%) 634 (30) 771 (39) ,0.001
Family history of MI, n (%) 160 (8) 224 (12) ,0.001
Waist-to-hip ratio 0.9560.08 0.9760.07 ,0.001
Data are presented as mean 6 SD or number (percentages).
1Difference between cases and controls were tested with the t test for
continuous variables and Fisher’s exact test for discrete variables.
2Not applicable because case and controls were matched for this variable.
doi:10.1371/journal.pone.0013081.t001
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Study Population
The design of the original population-based case-control study
has been described in detail elsewhere[13]. The catchment area
for this study comprised 7071 km
2 and 2,057,000 culturally
Hispanic individuals living in Costa Rica. This area included 36
counties in the Central Valley of Costa Rica representing a full
range of socioeconomic levels, as well as urban, periurban, and
rural lifestyles. Medical services for all residents of this area were
provided by 6 large hospitals, which are part of the National Social
Security System. Eligible case participants were men and women
who were survivors of a first MI as diagnosed by a cardiologist at
any of the 6 recruiting hospitals in the catchment area between
1994 and 2004. Since this study was designed to draw cases and
controls who were representative of the general population and the
intent was that cases should differ from controls only by the case
definition, the presence of other cardiovascular conditions was not
used to exclude controls (or cases). Control participants were
randomly selected using data from the National Census and
Statistics Bureau of Costa Rica. Control participants were
ineligible if they had ever had an MI. The controls in this study
were matched to cases by assigning participants to strata based on
age groups (65 y), sex, and area of residence (county). Four
controls were excluded from the study because they were assigned
to strata for which there were no matching cases, resulting in 1987
cases and 2147 controls. Study and consent documents were
approved by the Human Subjects Committee of both the Harvard
School of Public Health and the University of Costa Rica—all
participants gave written informed consent.
Genotype Determination
KIF6 Trp719Arg genotypes were determined for all study
participants using an allele–specific real-time PCR genotyping
assay[14] at a core facility. The DNA was standardized to 10 ng/
mL using PicoGreen (Molecular Probes, Invitrogen Corp,
Carlsbad, CA) fluorescent dye. The Trp719Arg genotypes
determined with this assay have been shown to be .99.8%
concordant with genotypes determined using an alternative
genotyping technology[4]. The primer sequences are available
upon request. Genotypes for the 39 ancestry informative markers
(AIMs) listed in the online supplement, Table S1, were previously
ascertained[12].
The admixture in this study population was previously
determined using the program ADMIXMAP and 39 AIMs to
estimate the proportion of admixture of the 3 ancestral ethnicities
for each subject[12]. The 39 AIMs were selected because they
showed large allelic frequency differences among the three
founding ancestral populations of the Costa Rican Central
Valley: Southern European, West-African and Amerindian
[10,15,16,17].
Statistical Analysis
Differences between baseline characteristics of patients were
assessed by the t-test (for continuous variables) or by the x
2 test (for
discrete variables). Deviations from Hardy–Weinberg expectations
were assessed using an exact test in controls. Conditional logistic
regression models were used to assess the association between
genotype and risk of MI while taking into account the matching
for age group, sex, and area of residence. SAS version 9 software
was used for all regression models. Models were adjusted for
smoking status (current vs. past or never smoked)[18], history of
hypertension (yes or no), history of diabetes (yes or no), waist-to-
hip ratio (quintiles based on the distribution in controls), family
history of MI (at least one of the parents had an MI before the age
of 60) and admixture (proportion of Amerindian and West-African
ancestral ethnicities). We did not adjust for plasma lipids because
pre-MI plasma lipid levels were not available. The available
plasma lipid levels were determined after the MI event and may
have been affected by the MI event, therapy or changes in lifestyle.
All P-values are 2-sided.
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Table 2. Association of KIF6 Trp719Arg with Myocardial Infarction.
Model 1
{ Model 2
1 Model 3
{
Genotype Case Control OR 95% CI p Value OR 95% CI p Value OR 95% CI p Value
ArgArg + ArgTrp 1202 1251 1.10 0.97–1.25 0.14 1.13 0.98–1.29 0.083 1.12 0.98–1.28 0.10
TrpTrp 785 896 ref ref ref
ArgTrp 952 966 1.13 0.99–1.29 0.074 1.16 1.01–1.34 0.040 1.15 1.00–1.33 0.049
ArgArg 250 285 1.00 0.83–1.22 0.98 1.01 0.82–1.25 0.93 1.00 0.81–1.24 1.00
{Cases and controls were matched for sex, age (65 y), and county of residence.
1Adjusted for smoking (current vs. never smoked), history of hypertension, history of diabetes, family history of MI, and waist-to-hip ratio.
{Adjusted for Model 2 covariates plus admixture.
OR = odds ratio; CI = confidence interval; ref = reference group.
doi:10.1371/journal.pone.0013081.t002
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